Journal article
Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada
Abstract
BACKGROUND: Heart failure (HF) with reduced ejection fraction represents approximately 50% of the 600,000 Canadians currently living with HF and over 90,000 new cases diagnosed each year. The angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, demonstrated superior efficacy in reducing cardiovascular death and HF hospitalization over standard of care therapy.
METHODS: The potential magnitude of benefit in Canada with respect to …
Authors
Huitema AA; Daoust A; Anderson K; Poon S; Virani S; White M; Rojas-Fernandez C; Zieroth S; McKelvie RS
Journal
CJC Open, Vol. 2, No. 5, pp. 321–327
Publisher
Elsevier
Publication Date
September 2020
DOI
10.1016/j.cjco.2020.03.015
ISSN
2589-790X